Comments
In a new study, scientists at Indian Council of Medical Research (ICMR)-National Institute of Virology have found that Covaxin demonstrated potential effectiveness against the Brazil variant of SARS-CoV-2.
This was announced by Biopharmaceuitcal company, Ocugen, Inc.
Ocugen is developing Hyderabad-based Bharat Biotech`s Covaxin for the US market.
"As previously disclosed, a study conducted by ICMR also suggested that Covaxin was effective against the UK variant, as well as the Indian double mutant variant," Ocugen said in a release
It is notable that the Brazilian variant, contains a mutation that was found in New York.
"These studies suggest that Covaxin vaccination may be effective against multiple SARS-CoV-2 variants. We are pleased to see the results of this study as it demonstrates the potential effectiveness of Covaxin against multiple variants, further strengthening our belief that this vaccine can potentially eliminate the possibility of mutant virus escape,” said Satish Chandran, chair of the vaccine scientific advisory board of Ocugen.
“The Ocugen team submitted a comprehensive drug master file with the FDA and is currently diligently preparing the EUA application,” . Shankar Musunuri, Chairman of the Board, Chief Executive Officer, and Co-founder of Ocugen said.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.